Zuma 23 Flyer by Wizzard123

CAR T-CELL THERAPY STUDY

RECRUITING NOW

In the U.S., Canada, Australia and Europe

ZUMA-23

Do you have an adult patient with newly diagnosed LBCL? Your patient could be a candidate for an investigational trial with CAR T if you can answer Yes to all the following questions:

Does your adult patient have histologically confirmed LBCL including: • DLBCL NOS

• HGBL

• Transformed DLBCL arising from FL or MZL *

Eligible if no prior treatment with anthracycline containing regimen"

Does your patient have high-risk disease? (IPI 4 or 5 at initial diagnosis)

Does your patient have adequate bone marrow and organ function (renal, hepatic, pulmonary and cardiac)?

Is your patient free from CNS involvement?

Is your patient about to start treatment or has received 1 cycle of R-chemotherapy? If yes to all of the above and to find out more about ZUMA-23, connect with the Kite Medical Affairs Team at booth # 1415 Scan QR code for more info on the ZUMA-23 trial, including the trial sites and a full list of inclusion and exclusion criteria, or visit.

https://clinicaltrials.gov/study/NCT05605899

The safety and efficacy of these investigational agents or investigational uses of marketed products have not been established. These uses have not been approved by the US Food and Drug Administration or other regulatory authorities. There is no guarantee that these therapies or uses will be commercialized. Please visit ClinicalTrials.gov for more information on trial eligibility criteria and other study details. ClinicalTrials.gov Identifier: NCT05605899. a Bridging therapy with R-CHOP or DA-EPOCH-R will be administered during the cell manufacturing period. b Participants will receive the investigator’s choice of either R-CHOP or DA-EPOCH-R for a total of 6 cycles (21-day cycle). References: 1. ClinicalTrials.gov. Accessed September 2023. https://clinicaltrials. gov/ct2/show/NCT05605899. 2. Data on file. Kite Pharma, Inc. 2022. Abbreviations: CAR: chimeric antigen receptor; CNS: centralnervous system; DLBCL: diffuse large B-cell lymphoma; ECOG PS: Eastern Cooperative Oncology Group performance status; FL: follicular lymphoma; HGBL: high-grade B-cell lymphoma; IPI: International Prognostic Index; LBCL: large B-cell lymphoma; MZL: marginal zone lymphoma; NOS: not otherwise specified; PI: principal investigator; QTC: qualified treatment centre; R: rituximab,DA-EPOCH-R: dose-adjust edetoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone. This material is funded and developed by Kite, a Gilead Company. KITE and the Kite Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc. © 2023 Kite Pharma, Inc. All rights reserved. MRC-00358 | November 2023

CAR T-CELL THERAPY STUDY

RECRUITING NOW

In the U.S., Canada, Australia and Europe

ZUMA-23

KT-US-484-0136

An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtegene Ciloleucel versus Standard of Care Therapy as First-Line Therapy in Participants with High-Risk Large B-Cell Lymphoma

Study Schematic 1L high-risk LBCL R-chemotherapy (1 cycle) Screening

Enrollment/Randomization 1:1

Axi-cel Treatment Arm

Standard-of-Care Arm

Leukapheresis

Continue with first-line standard of care R-chemotherapy: b • R-CHOP, or • DA-EPOCH-R

Bridging Therapya

Lymphodepleting Chemotherapy Axicabtagene ciloleucel infusion. Prophylactic corticosteriods (optional)

First disease assessment

Follow-up Period